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Persistent serum positivity for antiphospholipid antibodies
(aPL) is required to diagnose antiphospholipid syndrome
(APS), an autoimmune disease characterized by recurrent
vascular thrombosis and/or pregnancy morbidity. Throm-
botic events might affect the arterial as well as the venous
district; obstetric complications encompass early or late
pregnancy losses and premature birth due to preeclampsia,
eclampsia, or HELLP syndrome (hemolysis, elevated liver
enzyme levels, and low platelet levels). According to the
Updated Sapporo criteria, aPL are currently detected by three
laboratory tests: solid-phase assays for antibodies against β2
glycoprotein I (anti-β2GPI antibodies) and cardiolipin (aCL)
plus lupus anticoagulant (LA), a functional assay.1 Notewor-
thy, aPL are not only APS biomarkers but also exert a direct
pathogenic role in mediating clinical events. In particular,
autoantibodies targeting β2-glycoprotein I (β2GPI), a single-
chain serum 43-kDa glycoprotein consisting of ﬁve domains
(D), have been extensively identiﬁed as the main pathogenic
subset.2 In vivo ﬁndings show that aPL are sufﬁcient per se to
induce pregnancy loss, but a second hit is required to trigger
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Abstract Persistent serum positivity for antiphospholipid antibodies (aPL) is required to diag-
nose antiphospholipid syndrome (APS), an autoimmune disease characterized by
recurrent vascular thrombosis and/or pregnancy morbidity. The current therapeutic
management of patients with thrombotic APS aims at preventing recurrences and
long-term complications by attenuating the procoagulant state. There is overall
consensus to reserve moderate-intensity anticoagulation to aPL-positive patients
with a previous venous thrombosis; the therapeutic options for those with a history
of arterial event comprise antiplatelet agents and high-intensity anticoagulation.
Unfortunately, thrombotic occurrences might occur despite adequate anticoagulation,
carrying a signiﬁcant burden of morbidity and mortality. The management of
refractory thrombotic APS and catastrophic APS is still not clear, warranting the issue
of recommendations. Vitamin-K antagonists are limited by signiﬁcant side effects, and
a careful weighting of risks and beneﬁts should be performed to reserve the optimal
treatment to each patient. To overcome these limitations, novel oral anticoagulants
have been introduced in the market, but their efﬁcacy in thrombotic APS has still to be
unraveled. The poor safety proﬁle and the scarce efﬁcacy of drugs acting on the
coagulation cascade explain why novel therapeutic approaches are currently under
investigation, to identify pharmacological tools speciﬁcally counteracting aPL-mediat-
ed prothrombotic effects.
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vascular events. The so-called two-hit hypothesis ﬁts well
with clinical evidence: aPL carriers develop thrombosis only
occasionally, usually when an additional prothrombotic risk
factor, such as arterial hypertension, supervenes. The asso-
ciation with concomitant risk factors, mainly infections, is
particularly striking for the catastrophic variant of APS
(CAPS), a rare and serious aPL-related manifestation charac-
terized bymultiple small-vessel thrombotic events occurring
concomitantly at different anatomic sites.3 Consequently,
aPL positivity is regarded as a prothrombotic risk factor,
carrying an increase—to a highly variable extent—of the
hazard of thrombosis. All the parameters contributing to
the risk of vascular events should be weighted to tentatively
assess the real clinical impact of aPL positivity: an associated
autoimmune disease, genetic and acquired cardiovascular
risk factors, and the aPL proﬁle. In this regard, it should be
remembered that the thrombotic risk increases with the
number of positive aPL tests: triple positive patients display
the highest vascular hazard. In addition, each aPL test confers
a characteristic thrombotic risk, with LA being appointed as
the strongest predictor of clinical events.4 The stratiﬁcation
of the risk of thrombosis is a key feature in the management
of individuals with aPL positivity. The treatment of asymp-
tomatic aPL carriers is highly controversial because of the
poor protection against thrombosis conferred by available
therapeutic options, while the need of a secondary throm-
boprophylaxis in aPL-positive patients is universally ac-
knowledged. The current therapeutic management of
patientswith thrombotic APS aims at preventing recurrences
and long-term complications by attenuating the procoagu-
lant state. There is overall consensus to reserve anticoagu-
lation at a target international normalized ratio (INR) of 2.0
to 3.0 (moderate-intensity anticoagulation) to aPL-positive
patients with a previous venous thrombosis; the therapeutic
management of those with a history of arterial event is more
debated. The poor agreement among clinicians ismirrored in
the different therapeutic options enlisted in available rec-
ommendations to manage APS patients with a history of
arterial thrombosis: antiplatelet agents, low- or high-inten-
sity anticoagulation.5Unfortunately, thrombotic occurrences
might occur despite adequate anticoagulation, carrying a
signiﬁcant burden of morbidity and mortality. In addition,
anticoagulant agents are limited by signiﬁcant side effects,
thuswarranting a carefulweighting of risks and beneﬁts. The
poor safety proﬁle and the scarce efﬁcacy of drugs acting on
the coagulation cascade explain why novel therapeutic ap-
proaches are currently under investigation, to identify phar-
macological tools speciﬁcally counteracting aPL-mediated
prothrombotic effects.
Treatment of aPL-Positive Subjects with a
First Venous Thrombosis
Deep venous thrombosis provides the most common APS
presenting event, being recorded in 31.7% of cases; pul-
monary embolism occurs in 9% of patients.6 As in the
general population, the initial treatment of aPL-related
venous thrombosis envisages unfractionated heparin
(UFH) or low-molecular-weight heparin (LMWH) for at
least 5 days, embraced with vitamin K antagonists
(VKAs). Anticoagulation is almost always prescribed at
moderate-intensity, but some authors support anticoagu-
lation at a target INR of 3.0 to 4.0 as a therapeutic option.5
Moderate-Intensity Anticoagulation
PROs: Standard anticoagulation at a target INR below 3.0 has
been shown to confer effective protection against venous
recurrences. In particular, the two randomized clinical studies
comparing moderate- and high-intensity anticoagulation in
patients with a deﬁnite APS diagnosis failed to report any
difference between the two regimens.7,8 Consequently, a
meta-analysis considering these two trials could not report
any difference in the rate of thrombosis recurrencebetween the
two regimens, althoughanalmost signiﬁcantexcess thrombotic
risk was observed with high-intensity anticoagulation.8 This
observation might reﬂect the strong difﬁculties that patients
experience in keeping INR in the high-intensity range: patients
in the high-intensity group presented an INR below the target
range for over 40% of the follow-up time, thus limiting the
interpretation of the efﬁcacy of high-intensity regimen.
CONs: Some retrospective studies suggested that the high-
intensity regimenwas more effective in preventing thrombotic
recurrence compared with low-intensity anticoagulation
among unselected APS patients and those with a history of
venous thrombosis.9 It should also be considered that many of
the studies in support of the equality of moderate- and high-
intensity regimens recruited patients presenting laboratory
tests not fulﬁlling criteria for full-blown APS. Even the two
randomized studies presented a few limitations, such as the
small sample size, the limited statistical power, and fewpatients
with a high-risk aPL proﬁle. The third is a strong bias: patients
on standard anticoagulant therapy with a previous venous
event and a high-risk aPL proﬁle, namely, those carrying triple
aPL positivity, presented a 45% recurrence rate over a 6-year
period.10 This body of evidence might thus suggest that stan-
dard-intensity anticoagulant therapy confers poor protection
against thrombotic recurrences in the high-risk group.
Debated Issue: Duration of Anticoagulation
Even though it is current practice to prescribe indeﬁnite
anticoagulation to APS patients with a history of venous
thrombosis, an increasing debate about the potential with-
drawal of anticoagulation in subjects with previous venous
thrombosis who turn aPL-negative has emerged. This is based
on two case series, where anticoagulation was safely termi-
nated among APS patients eventually becoming aPL nega-
tive.11,12 Accordingly, it has been recently suggested that APS
patients with a ﬁrst venous event and a low-risk aPL proﬁle
plus a known transient precipitating risk factor (second hit)
could be candidate for 3 to 6 months of anticoagulation,
provided that there is a normal D-dimer and no ultrasono-
graphical evidence of residual thrombosis. This approach is
supported by a randomized trial comparing 1- to 3-month
anticoagulation in patients with venous thrombosis and a
transient reversible risk factor: subgroup analysis showed
that aPL positivity tested at the time of randomization is
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not predictive of venous recurrence.13 Caution should be
considered when stopping anticoagulation: the risk of vascu-
lar recurrence is highest in the 6 months following drug
discontinuation.14
Treatment of aPL-Positive Subjects with a
First Arterial Thrombosis
Arterial thrombosis provides the presentingmanifestation in
27% of patients; most commonly, the cerebral district is
involved. Among noncerebral thrombosis, the most common
presentation is myocardial infarction.6 There are two differ-
ent therapeutic approaches to aPL-positive subjects who
experience an arterial event in noncerebral districts. Some
experts commonly prescribe moderate-intensity anticoagu-
lation, while other clinicians opt for VKA anticoagulation at a
target INR of 3.0 to 4.0.5
Moderate-Intensity Anticoagulation
PROs: The efﬁcacy of moderate-intensity anticoagulation is
supported by the two randomized controlled trials that also
recruited patients with a history of arterial events, even
though less represented than those with venous thrombosis.
As previously discussed, these two studies are not in support
of the advantages offered by high-intensity compared with
moderate-intensity anticoagulation.7,8
CONs: The main critical issue in the management of
patients with arterial thrombosis concerns the risk of a
new thrombotic event despite adequate treatment. The
risk of recurrence is particularly relevant in case of a ﬁrst
arterial thrombosis, as these patients have always been
considered at higher risk of recurrent event, almost invari-
ably involving the same circulatory district. This belief is
mainly supported by the only survey analyzing arterial and
venous events separately and two cohort studies, all
concordantly concluding that the risk of recurrence is higher
for arterial than venous events.9 This evidence is, however, in
clash with the results emerging from a study considering
high-risk triple-positive APS patients, where the presenting
event did not predict the site of the recurrence.10
High-Intensity Anticoagulation
PROs: Some clinicians prescribe a high-intensity regimen to
APS patients with arterial thrombosis, advocating that in
many studies oral anticoagulation to a standard target INR of
2.0 to 3.0 did not offer a sufﬁcient protection against
recurrences.9 The choice of a high-intensity regimen is
further supported by the higher recurrence risk experienced
by APS patients with previous arterial events, as suggested in
some—but not all—studies.9 In a cohort of triple positive APS
subjects with a history of arterial thrombosis on standard
anticoagulation, a 47% recurrence rate was registered,
suggesting its poor efﬁcacy.10
CONs: The main limitation affecting the use of anticoagu-
lants at high intensity is the risk of bleeding. A 2007 system-
atic review reported a yearly bleeding rate between 0.57 and
10%.15When only recent studies exploiting a target INR of 2.0
to 3.0 are taken into account, the annual bleeding rate drops
down to 0.8 to 1.6%.9 Undoubtedly, the risk of bleeding
increases progressively with the rising of anticoagulation
intensity. To note, at higher intensity of anticoagulation, there
are wider INR ﬂuctuations contributing to the instauration of
a thrombogenic status. It should be stressed that themortality
rate due to aPL-related thrombosis is higher than themortali-
ty rate due to bleeding: the single study speciﬁcally address-
ing the risk of bleeding in APS reported no fatal bleeding
episodes, with precipitating factors identiﬁed in all cases.16
Treatment of aPL-Positive Subjects with
Stroke
aPL-mediated events present a particular tropism for the
cerebral circulation: the most frequent site of arterial throm-
bosis in APS is the cerebral vasculature. Indeed, stroke is the
presenting clinical manifestation in 13% of cases, while 7% of
APS patients develop a transient ischemic attack at disease
presentation. Stroke accounts for signiﬁcant morbidity and
mortality: in a large European cohort, 13% of deaths were due
to cerebral ischemia, at a mean age of 42 years.17 Besides
anticoagulants, the therapeutic armamentarium in case of
cerebral arterial thrombosis also comprises antiplatelet
agents.
Low-Dose Aspirin
PROs: The use of low-dose aspirin (LDASA) in aPL-mediated
stroke is supported by the Antiphospholipid Antibodies and
Stroke Study (APASS). In this randomized controlled trial,
when only aPL-positive patients were considered, aspirin
given at a daily dose of 325 mg was as effective as low-
intensity anticoagulation in stroke secondary prevention.18
CONs: In the APASS study, many patients had aCL positivi-
ty at low titers, and positivity in aPL tests was not conﬁrmed
12 weeks apart. Subjects with baseline positivity for both LA
and aCL tended to have a higher event rate (31.7%) than those
negative for both antibodies (24%). These ﬂaws prevent the
extrapolation of results to patients with deﬁnite APS.18
Low-Dose Aspirin plus Anticoagulation
PROs: The combo approach of LDASA plus moderate-intensi-
ty anticoagulation was proposed as a therapeutic option in
stroke patients diagnosed with APS in a 2009 randomized
controlled trial. This study reported a lower rate of stroke
recurrences in the arm receiving LDASA plus warfarin com-
pared with LDASA alone; the cumulative stroke-free survival
was 74 and 25%, respectively.
CONs: This study is limited by a small sample size and few
details about aPL proﬁles and limited data on stroke
recurrences.19
New Therapeutic Approaches to Thrombotic
APS
Novel Anticoagulants
A novel class of anticoagulants, the direct oral anticoagulants
(DOACs), has been synthesized. These oral pharmacological
agents are highly selective, each inhibiting a single
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coagulation enzyme.Dabigatran acts as a thrombin inhibitor:
it potently directly binds to thrombin and reversibly blocks
its interaction with substrates. Rivaroxaban, apixaban, and
edoxaban are direct FXa inhibitors.20 Dabigatran and rivar-
oxaban were used in some cohorts of APS patients: in a
cohort of 26 FrenchAPS patients, a single recurrent event and
two bleeding episodeswere registered; a UK cohort of 35 APS
subjects proved rivaroxaban to be safe.20 Several randomized
controlled clinical trials are currently assessing rivaroxaban
versus low-intensity anticoagulation in APS management.
The RAPS (Rivaroxaban in APS) trial has been promoted by a
UK group; it is a phase II/III study that has recruited 156 APS
patients with a history of venous thromboembolism21; a
Spanish phase III trial has recruited 218 patientswith venous
or arterial events; the TRAPS (trial on rivaroxaban in high-
risk patients with APS) trial, an Italian noninferiority study
considering exclusively triple positive APS patients, is still
recruiting22; the ASTRO-APS (Apixaban for the secondary
prevention of thromboembolism among patients with APS),
a randomized open-label trial, will randomize APS patients
to adjusted-dose warfarin or apixaban twice daily.23
PROs: Thanks to the dose-dependent predictable antico-
agulant effect, DOACs can be administered at a ﬁxed dose. In
addition, as they are metabolized by a system different from
cytochrome P450, dietary constituents, alcohol, and drugs do
not interact with DOACs. Therefore, DOACs do not require
routine monitoring of anticoagulant intensity, with a signif-
icant improvement in quality of life for patients.24
CONs: DOACs are burdened by a signiﬁcant bleeding risk.25
Several case reports of thrombotic recurrence in concomi-
tance of switching from warfarin to rivaroxaban have been
published, although possibly reﬂecting a publication
bias.26–28
Adjuvant Therapies in the Treatment of Thrombotic
APS
Hydroxychloroquine
Hydroxychloroquine (HCQ) is an antimalarial drug with immu-
nomodulatory, anti-inﬂammatory, and antithrombotic action.
Invitro, HCQhas beendemonstrated to (1) prevent activation of
Toll-like receptor (TLR) 3, TLR7, and TLR9; (2) inhibit the
processing and the presentation of antigens; (3) reduce serum
immune complexes; (4) impair platelet aggregation induced by
collagenorADP; (5) downregulatemembraneglycoprotein (GP)
IIb/IIIa expression on platelets activated by aPL; (6) reverse the
formation of aPL-β2GPI–phospholipid bilayer complexes; and
(7) prevent the aPL-induced disruption of the Annexin A5
shield. Its antithrombogenic properties have been conﬁrmed
in vivo: HCQ injection to mice induced a dose-dependent
decrease in thrombus size. In patients, HCQexerts antilipidemic
effects with lower levels of triglycerides and low-density lipo-
protein cholesterol.29 In primary thrombotic APS, patients
receiving a dual regimen including HCQ and oral anticoagula-
tion had a lower recurrence rate compared with those on
anticoagulants only. However, data extrapolation is affected
by the small sample size (40 patients) and the limited follow-up
(36 months).30
Statins
The observation that low high-density lipoprotein choles-
terol and high triglyceride levels are the most frequent
cardiovascular risk factors among APS patients suggests
that statins might be beneﬁcial in the prevention of aPL-
mediated thrombosis. In APS setting, these pharmacological
compounds exert additional pleiotropic anti-inﬂammatory
and antithrombotic effects. In vitro, statins have been dem-
onstrated to (1) inhibit the synthesis of tissue factor (TF) in
endothelial cells (ECs); (2) suppress endothelial adhesive-
ness induced by anti-β2GPI antibodies; (3) reduce the
adhesion of monocytes to the vascular endothelium; and
(4) prevent VCAM upregulation by aPL. In vivo, ﬂuvastatin
reduced the size of the thrombus induced by aPL infusion
and the leukocyte adhesion to EC. Ex vivo studies provide
consistent ﬁndings. In a trial considering 42 APS patients, a
30-day ﬂuvastatin course decreased several thrombogenic
and inﬂammatory mediators in monocytes; a signiﬁcant
reduction in some proinﬂammatory and procoagulant
parameters was reported after a 3-month treatment with
ﬂuvastatin in 41 aPL asymptomatic carriers.31
Vitamin D
Among APS patients, the frequency of the deﬁciency of
vitamin D ranges between 10 and 50%; insufﬁciency may
occur in up to 70% of patients.2 Low levels of vitamin D are
more frequently detected among subjects with arterial and
venous thrombosis as well as with noncriteria APS manifes-
tations. In vitro, vitamin D acts as an immunomodulator and
antithrombotic agent, mainly preventing anti-β2GPI anti-
body-mediated TF expression. Thus, vitamin D supplementa-
tion might be beneﬁcial in the secondary prevention of
thrombotic events.32
Intravenous Immunoglobulins
The therapeutic potential of intravenous immunoglobulins
(IVIg) in APS is suggested by in vivo and in vitro models. IVIg
were shown to (1) partially neutralize LA phenomenon and
prevent aCL binding to the antigen; (2) inactivate idiotype-
bearing B cell clones; (3) increase IgG catabolism; (4) block
complement activation; (5) inhibit Fcγ receptor on macro-
phages; and (6) downregulate proinﬂammatory cytokine.
Treatment with IVIg inhibited aPL thrombogenic effects,
reducing aCL levels. There are some published reports of
successful treatment with IVIg of aPL-related clinical man-
ifestations, mainly hematological. A response to treatment
was reported in all patients but one.33
Anti-B Cell Agents
B lymphocytes exert a key role in APS etiopathogenesis: they
synthetize autoantibodies, promote germinal center forma-
tion, and induce cytokines. In lupus-prone mice, treatment
with IgGagainst B cell activating factor (BAFF) receptor didnot
affect aCL development but prolonged survival, preventing
aPL-related thrombosis. Therefore, anti-B cell agents, such as
belimumab (an anti-BAFF monoclonal antibody) and ritux-
imab (an anti-CD20 monoclonal antibody), might be beneﬁ-
cial in APS. Interestingly, in belimumab-treated lupus
Seminars in Thrombosis & Hemostasis
Management of Thrombotic APS Chighizola et al.
patients, seroconversion toward aCL negativity was reported.
In the clinical setting of APS, experience of B cell inhibition is
still restricted to rituximab. In themulticenter registry by the
Spanish Study Group of Biological Agents in Autoimmune
Diseases (BIOGEAS), a beneﬁcial effect was observed in 92% of
12 cases.34 In the Rituximab in Antiphospholipid Syndrome
study (RITAPS), an open-label phase IIa descriptive pilot study,
20 patients with noncriteria APS manifestations refractory to
conventional therapieswere treatedwith rituximab, resulting
in a satisfactory control of some noncriteria manifestations,
without affecting aPL proﬁle.35 Given this body of evidence,
the task force on APS treatment trends claimed a therapeutic
role for anti-B cell agents in APS cases with unresponsive
hematologic and microangiopathic manifestations.34 Severe
acute thrombotic exacerbations have been reported in two
APS lupus subjects on rituximab, thus suggesting caution.34
Treatment of APS Patients with Thrombotic
Recurrences
Approximately 3 to 24% of APS patients develop recurrent
events even during adequate treatment.9 Despite the impor-
tant morbidity and mortality effects that recurrences yield,
clear recommendations to manage these situations are still
lacking. Indeed, no randomized clinical study has ever as-
sessed themanagement of patientswho had a thrombosis on
anticoagulation. The current clinical approach envisages ﬁrst
the assessment of INR at the time of the recurrence. If the
thrombotic event occurred at a subtherapeutic INR range, a
moderate-intensity regimen can be continued, keeping the
INR in the therapeutic range. In case of an INR within the
therapeutic range, the intensity of anticoagulation should be
increased to a target INR of 3.0 to 4.0.
Low-Molecular-Weight Heparin
Switching to long-term LMWH may also be considered as a
safe and effective alternative to warfarin. This approach was
even considered in the evidence-based consensus guidelines
formulated at the 13th International Congress on Antiphos-
pholipid Antibodies.5 The efﬁcacy of LMWH in thrombotic
recurrences emerged outside APS ﬁeld: the 2003 CLOT
(Randomized Comparison of Low-Molecular-Weight Hepa-
rin versus Oral Anticoagulant Therapy for the Prevention of
Recurrent Venous Thromboembolism in Patients with Can-
cer) study stated that dalteparin was even more effective
than warfarin in reducing the risk of recurrent embolic
events among cancer patients.36 The rationale of prescribing
LMWH is even stronger for APS patients. Indeed, heparin
exerts pleiotropic effects, beyond its anticoagulant action.
Heparin (1) interacts directly with β2GPI (the primary
heparin-binding site is located on the second positively
charged site within DV of β2GPI); (2) enhances the plas-
min-mediated cleavage of Lys317-Thr318 site in β2GPI,
resulting in a diminished ability of β2GPI to recognize
phospholipids and the consequent impairment of the pro-
thrombotic activity of anti-β2GPI antibodies; and (3) inhib-
its, at variance of other anticoagulants, complement
activation in animal models of obstetric APS, thus preventing
aPL-mediated fetal loss. LMWH use is limited because of the
subcutaneous administration and side effects (heparin-in-
duced thrombocytopenia, osteoporosis).9
Dual Antiplatelet Treatment
Another possible approach envisages a dual antiplatelet
treatment (different combination of LDASA, ticlopidine,
clopidogrel, and cilostazol), based on the results of a Japanese
study where, among 82 APS patients with relapsing arterial
events, no recurrence was documented.37
Low-Dose Aspirin
In patients with recurrent arterial events, LDASA could be
added to anticoagulant treatment, even though this option is
burdened bya higher bleeding risk. To date, only a small, low-
quality randomized controlled trial has shown that combi-
nation therapy was more effective than aspirin alone in the
secondary prevention of aPL-related stroke.18
Rituximab and Eculizumab
Novel biologic agents have also been proposed as therapeutic
option for refractory thrombotic APS. In a 2012 review paper,
27 APS patients who received rituximab were identiﬁed,
with decrease of aPL titers and clinical improvement in all
cases.38 Eculizumab is a humanized monoclonal antibody
which binds with high afﬁnity to C5. It inhibits the cleavage
of C5 to C5a and C5b, thus preventing the generation of
membrane attack complex. The potent anaphylatoxic, proin-
ﬂammatory, and chemotactic C5a plays a central role in APS:
it induces the expression of TF on ECs and neutrophils; in
vivo, C5 mediates ﬁbrin deposition in aPL-induced thrombi.9
There is a single report of eculizumab use in the secondary
thromboprophylaxis of APS. This is the case of a 59-year-old
APS woman who received eculizumab while undergoing
bypass surgery to treat a critical vascular occlusion of the
femoral artery.39 Eculizumab has also been proposed in the
management of APS patients who required renal transplan-
tation. In three kidney transplant recipients, eculizumab
improved posttransplant aPL-mediated thrombotic micro-
angiopathy resistant to plasmapheresis. In an additional
series of three patients receiving anticoagulation and eculi-
zumab, no systemic thrombotic events or early graft losses
occurred after a follow-up between 4 months and 4 years.9
Intravenous Immunoglobulins
Another option that could be exploited is the addition to
standard treatment of IVIg, as suggested by twoopen studies.
IVIg were effective in ﬁve APS patients with relapsing
thrombosis: no new thrombotic event occurred at 5-year
follow-up.40 In the other study, IVIg prevented thrombosis
when added to conventional therapy in seven patients with
refractory APS at 2 years.33
Treatment of Catastrophic APS
Most of the available evidence for CAPS management comes
from an international registry by the European Forum on
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Anti-phospholipid Antibodies. In this registry, two thera-
peutic approaches were identiﬁed as the most effective in
CAPS. The ﬁrst one comprised anticoagulation, corticoste-
roids, and plasma exchange, with a 77.8% recovery rate.
Anticoagulation, corticosteroids, plasma exchange, and/or
IVIg allowed controlling the disease in 69% of cases. Plasma
exchange is specially indicated when schistocytes are pres-
ent, and should be initiatedwithin 12 hours from the onset.41
When these therapeutic approaches do not lead to disease
control, second-line agents such as rituximab and eculizu-
mab can be used, even though experience is only anecdotal.
In literature, there are 20 reports of rituximab prescription to
CAPS patients, differently combined with anticoagulation,
high doses of steroids, plasma exchange, and IVIg, with a
lower mortality rate. Eculizumab has been administered to a
few CAPS patients refractory to all the other therapeutic
strategies; a positive effect was reported in two cases.42
Treatment of Thrombotic APS in the Near
Future
The currently available strategies in APS management are
limited to agents counteracting coagulation; however, as
already discussed, these drugs display several limitations
and are not effective in all patients. An alternative approach
aims at preventing the prothrombotic effects via the inhibi-
tion of the cellular mechanisms engaged by aPL. The ﬁrst
strategy could envisage the prevention of aPL binding to target
cells; this could be pursued thanks toTIFI,which is a 20-amino
acid synthetic peptide spanning Thr101 to Thr120 of ULB0-
HCMVA fromhuman cytomegalovirus. TIFI is similar toβ2GPI-
DV, where the phospholipid-binding site is located. TIFI thus
competes with β2GPI for binding to phospholipids in the cell
membrane and is not targeted by aPL. In vitro and in vivo
ﬁndings suggest its efﬁcacy: TIFI inhibited the binding of
labeled β2GPI to human ECs and mouse monocytes, and its
infusion to animals decreased the size of aPL-mediated
thrombi and reduced the binding of ﬂuoresceinated β2GPI
to the endothelium.9 Similarly, a peptide homologous to
β2GPI-DI, the most relevant epitope involved in β2GPI/anti-
β2GPI antibody binding, has been synthetized. This peptide
inhibits the prothrombotic effects mediated by aPL both in
vivo and in vitro.43 Another approach exploits a nonpatho-
genicmonoclonal anti-DI antibody,MBB2ΔCH2. This is a CH2-
deletedvariantof thenovelmonoclonal antibody targetingDI-
β2GPI, MBB2,which exerts prothrombotic effects.MBB2ΔCH2
does not activate the complement cascade, thus not inducing
clotting, but competes with circulating aPL for binding to
β2GPI. When infused to rats together withMBB2, MBB2ΔCH2
prevented the MBB2-procoagulant effects.44 The immunodo-
minant epitope DI is a cryptic and conformation-dependent
structure; the surface exposition of the critical B cell structure
might be inducedbyseveral factors, including oxidative stress.
Indeed, oxidative conditions favor the formation of disulﬁde
bonds within the molecule, which lead to the unmasking of
the relevant epitope.2 This process is catalyzed by the enzyme
protein disulphide isomerase (PDI); therefore, quercetin-3-
rutinoside, an inhibitor of this enzyme, might be effective in
APS. In animal models, PDI inhibitors treated thrombosis. In
monocytes, inhibiting the intracellular reactive oxygen spe-
cies results in the prevention of the upregulation of aPL-
induced TF.31 Consequently, antioxidant compounds as N-
acetylcysteine, vitamin C, and coenzyme Q10 might play a
beneﬁcial role in the management of APS patients.
The pharmacological interference with the mediators
engaged by aPL could provide another option: aPL induce a
proinﬂammatory and procoagulant endothelial phenotype
upregulating cellular adhesion molecules, TF, TNF-α, and IL-
6. Several drugs available over the counter inhibit the
expression of TF, the major initiator of the clotting cascade.
This is the case of ACE inhibitors, dilazep and dipyridamole.
In particular, both dilazep and dipyridamole prevent TF
upregulation in monocytes induced by polyclonal IgG puri-
ﬁed from APS patients.9 To date, the role of these compounds
in APS management has been scarcely documented. Similar-
ly, it can be envisaged that blocking of TNF-α and IL-6 with
biologic agents might be beneﬁcial.34
aPL-inducedeffectson theendotheliumaremainlymediated
by autoantibody reactivity with β2GPI on the EC membrane.
Therefore, antagonists or neutralizing monoclonal antibodies
acting on the potential receptors involved in β2GPI interaction
with ECs (Annexin A2, TLR2, TLR4, heparan-sulfate, and
ApoER2′3) might be effective in APS. β2GPI-DV binds the A1
ligand–binding type A module of ApoER2′; in vitro, a dimer
constituted of two A1molecules has been reported to block the
binding of anti-β2GPI antibody/dimerized β2GPI immune com-
plexes to negatively charged phospholipids and ApoER2′, to a
more potent extent than monomeric A1. Such a dimeric mole-
culewas shown tobe effective in twoanimalmodels of APS.45 In
platelets, the interaction of aPL with cell surface is mediated by
GPIIb/IIIa. Abciximab, a speciﬁc GPIIb/IIIa inhibitor, commonly
prescribed to patients with stroke and acute coronary syn-
dromes, can thus be proposed for APS management. Down-
stream of cell receptors, nuclear factor κB (NFκB) and p38
mitogen-activated protein kinase (p38MAPK), are involved in
aPL-induced EC andmonocyte activation. Therefore, blockers of
the downstream mediators engaged by aPL may reverse the
prothrombotic phenotype: NFκB and p38MAPK inhibitors can
prevent prothrombotic and proinﬂammatory effects induced
by aPL treatment in vitro. DHMEQ, an inhibitor of NFκB,
ameliorated the prothrombotic state induced in mice by the
treatment with the monoclonal antibody WB-6.31 aPL have
been recently demonstrated to recruit themammalian target of
rapamycin (mTOR) via the phosphatidylinositol 3-kinase-AKT
pathway. mTOR is a kinase modulating cellular growth, prolif-
eration, and apoptosis. The mTOR inhibitor sirolimus has been
used in patients with APS nephropathy requiring kidney trans-
plantation, leading to a higher rate of functioning allograft at
144 months and a decreased vascular proliferation on biopsy
compared with the standard regimen arm.46
Conclusion
The treatmentof thromboticAPSis a rather relevant issuefrom
a socioeconomic point of view. Although there are no sound
epidemiological studies on the prevalence of aPL or APS in the
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general population, thediseasehasbeen estimated to affect 40
to 50 individuals per 100,000 persons, usually presenting in
early adulthood.47,48 These epidemiological data imply that
APS carries high socioeconomic morbidity and mortality,
making pivotal the optimal management of APS patients.
Antiplatelet and anticoagulant agents still provide the corner-
stone of APS treatment, as suggested in available recommen-
dations5 (►Table 1). However, it should be borne inmind that
most evidence in support of these treatments comes from
studies including patients not fulﬁllingAPS laboratory criteria.
Indeed, several limitationsﬂaw these studies,mainly concern-
ing aPL testing. Most studies do not fulﬁll international
requirements in terms of number of aPL tests performed,
the conﬁrmation of aPL positivity, and the choice of aPL cutoff.
In this scenario, it isnot surprising that inmulticentercohortof
patients with longstanding APS, anticoagulation appears not
to protect against recurrences at long term. The poor beneﬁt
exerted by anticoagulants is further suggested by the fact that
55%ofAPSpatientspresentedwithorgandamage.49Thescarce
protection conferred by anticoagulants might underline the
necessity of a “tailored treatment strategy.” In other words, a
more aggressive treatment should be reserved to aPL-positive
patients with a high-risk aPL proﬁle and additional prothrom-
botic risk factors. Consequently, a better stratiﬁcation of aPL-
positive patients upon the aPL proﬁle (triple/double positivity
vs. single positivity) and associated cardiovascular risk factors
is mandatory to accurately evaluate themagnitude of the risk.
Novel diagnostic and prognostic tools, such as antidomain
antibodies, may allow an even more accurate risk stratiﬁca-
tion. It would be advisable to soon assess the potential effects
of a strict control of cardiovascular status and the beneﬁt of
pleiotropic agents such as statins and HCQ on outcome,
hopefully leading to a better disease control. Given the many
limitations of available treatments, it is to be hoped that the
novel pharmacological agents that have been identiﬁed in
these recent years will optimize APS management in the
near future.
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